These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28596107)

  • 21. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
    Motabar O; Goldin E; Leister W; Liu K; Southall N; Huang W; Marugan JJ; Sidransky E; Zheng W
    Anal Bioanal Chem; 2012 Jan; 402(2):731-9. PubMed ID: 22033823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.
    Shachar T; Lo Bianco C; Recchia A; Wiessner C; Raas-Rothschild A; Futerman AH
    Mov Disord; 2011 Aug; 26(9):1593-604. PubMed ID: 21618611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recently discovered functions of glucosylceramides in plants and fungi.
    Warnecke D; Heinz E
    Cell Mol Life Sci; 2003 May; 60(5):919-41. PubMed ID: 12827281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sterylglucosides in Fungi.
    Pereira de Sa N; Del Poeta M
    J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocerebroside storage in normal monocyte cultures.
    Hardy B; Teitelman-Weissman B; Chazan S; Neri A
    Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolism of glucocerebrosides - From 1965 to the present.
    Futerman AH; Platt FM
    Mol Genet Metab; 2017; 120(1-2):22-26. PubMed ID: 27955980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.
    Gal AE; Pentchev PG; Massey JM; Brady RO
    Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3083-6. PubMed ID: 290986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of conjugated sterols in eggplant. Part 1. UDP-glucose : sterol glucosyltransferase.
    Potocka A; Zimowski J
    Acta Biochim Pol; 2008; 55(1):127-34. PubMed ID: 18196184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease.
    Zigdon H; Meshcheriakova A; Farfel-Becker T; Volpert G; Sabanay H; Futerman AH
    FEBS Lett; 2017 Mar; 591(5):774-783. PubMed ID: 28186340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gaucher disease.
    Butters TD
    Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceramide glucosylation in bean hypocotyl microsomes: evidence that steryl glucoside serves as glucose donor.
    Lynch DV; Criss AK; Lehoczky JL; Bui VT
    Arch Biochem Biophys; 1997 Apr; 340(2):311-6. PubMed ID: 9143336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging roles for conjugated sterols in plants.
    Ferrer A; Altabella T; Arró M; Boronat A
    Prog Lipid Res; 2017 Jul; 67():27-37. PubMed ID: 28666916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.
    Ron I; Horowitz M
    Hum Mol Genet; 2005 Aug; 14(16):2387-98. PubMed ID: 16000318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is E326K glucocerebrosidase a polymorphic or pathological variant?
    Liou B; Grabowski GA
    Mol Genet Metab; 2012 Mar; 105(3):528-9. PubMed ID: 22227325
    [No Abstract]   [Full Text] [Related]  

  • 38. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
    McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
    Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
    Sinclair GB; Jevon G; Colobong KE; Randall DR; Choy FY; Clarke LA
    Mol Genet Metab; 2007 Feb; 90(2):148-56. PubMed ID: 17079175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocerebrosidases catalyze a transgalactosylation reaction that yields a newly-identified brain sterol metabolite, galactosylated cholesterol.
    Akiyama H; Ide M; Nagatsuka Y; Sayano T; Nakanishi E; Uemura N; Yuyama K; Yamaguchi Y; Kamiguchi H; Takahashi R; Aerts JMFG; Greimel P; Hirabayashi Y
    J Biol Chem; 2020 Apr; 295(16):5257-5277. PubMed ID: 32144204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.